Phase II Trial of Weekly Bortezomib in Combination With Rituximab ...

Phase II trial of weekly bortezomib in combination with rituximab in ...

The combination of weekly bortezomib and rituximab showed significant activity and minimal neurologic toxicity in patients with relapsed WM.

Phase II trial of weekly bortezomib in combination with rituximab in ...

This study aimed to determine the activity and safety of weekly bortezomib and rituximab in patients with untreated Waldenström Macroglobulinemia (WM).

Phase II Trial of Weekly Bortezomib in Combination With Rituximab ...

The combination of weekly bortezomib and rituximab showed significant activity and minimal neurologic toxicity in patients with relapsed WM. Formats available.

Phase II Trial of Weekly Bortezomib in Combination with Rituximab ...

My Account ... Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's ...

Phase II Trial of Weekly Bortezomib in Combination With Rituximab ...

In summary, we demonstrate that the combination of weekly bortezomib and rituximab showed a high response rate that included CRs in patients ...

Phase II Trial of Weekly Bortezomib in Combination with Rituximab ...

Majority of patients (78%) completed treatment per protocol. At least minimal response (MR) or better was observed in 81% (95% CI: [65,92]) with ...

Phase II Trial of Weekly Bortezomib in Combination with Rituximab ...

The combination of weekly bortezomib and rituximab showed significant activity and minimal neurological toxicity in patients with relapsed WM.

Phase II trial of weekly bortezomib in combination with rituximab in ...

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Irene M. Ghobrial ...

Phase II Trial of Weekly Bortezomib in Combination with Rituximab ...

The combination of weekly bortezomib and rituximab showed significant activity and minimal neurological toxicity in patients with untreated WM.

Multi-center phase II trial of bortezomib and rituximab maintenance ...

We conducted a multicenter, phase II trial of bortezomib given in combination with rituximab as maintenance in MCL patients after consolidative auto-HCT.

A Multicenter Phase II Study of Twice-Weekly Bortezomib plus ...

On the basis of these findings, we performed a phase II study of B combined with rituximab (R) in patients with relapsed follicular lymphoma (FL) ...

Phase II Trial of Weekly Bortezomib in Combination With Rituximab ...

Request PDF | Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstrom Macroglobulinemia | This ...

Phase I Trial of Weekly and Twice-Weekly Bortezomib with ...

Results: Both schedules of R-CBorP (rituximab, cyclophosphamide, bortezomib, and prednisone) were well tolerated. Most toxicities across all dose levels and ...

Bortezomib combined with rituximab and dexamethasone is an ...

This was a single-center, phase II study of bortezomib combined with rituximab and dexamethasone in patients with relapsed/refractory MCL. The primary endpoint ...

eCommons@AKU

Multicenter Randomized Phase II Study of Weekly or. Twice-Weekly Bortezomib Plus Rituximab in Patients With. Relapsed or Refractory Follicular or Marginal- ...

Phase 2 trial of rituximab and bortezomib in patients with relapsed or ...

In vitro studies in mantle cell lymphoma (MCL) cell lines and patient-derived cells have demonstrated synergistic apoptosis with combined ...

Bortezomib plus rituximab versus rituximab alone in patients with ...

Bortezomib and rituximab have shown additive activity in preclinical models of lymphoma, and have been shown to be active and generally well ...

The Combination of Weekly Infusion of Rituximab and Bortezomib Is ...

Patients and methods. The study was a prospective single arm phase II trial, designed on Simon two-stage Optimal Design. Primary end-point was ...

Phase II Trial of Weekly Bortezomib in Combination With Rituximab ...

Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia · Journal of Clinical ...

A Multicenter Phase II Study of Twice-Weekly Bortezomib plus ...

Request PDF | A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up ...